ASCO – Talk Bio

Actuate Therapeutics’ Pancreatic Cancer Drug Elraglusib Shows Survival Benefit in Phase 2 Study

4 days ago talkbio0Tagged 130-nm albumin-bound paclitaxel, Actuate, ASCO, Elraglusib, gemcitabine, Metastatic Pancreatic Ductal Adenocarcinoma, Midline (qualifier value), Pancreatic carcinoma, Survival

Actuate Therapeutics; Elraglusib; Pancreatic cancer; Phase 2 trial; Median overall survival; Gemcitabine; Nab-paclitaxel; Metastatic pancreatic ductal adenocarcinoma; Survival benefit; ASCO 2025

OSE Immunotherapeutics Reports 65% Overall Survival Rate in Phase 2 Cancer Vaccine Trial at ASCO 2025

5 days ago talkbio0Tagged ASCO, neo-epitope cancer vaccine, OSE Immunotherapeutics, Pancreatic carcinoma, Phase 2, survival rate, Tedopi

OSE Immunotherapeutics; Tedopi; ASCO 2025; pancreatic cancer; neo-epitope cancer vaccine; phase 2; overall survival rate

Bristol Myers CMO Addresses LAG-3 Concerns After Opdualag’s Adjuvant Melanoma Setback at ASCO 2025

5 days ago talkbio0Tagged Adjuvant Melanoma, ASCO, Clinical Trials, lymphocyte-activation gene 3 protein, human, Malignant neoplasm of lung, Myers, Opdivo, Opdualag, relatlimab, squibb

Opdualag; Bristol Myers Squibb; LAG-3; lung cancer; adjuvant melanoma; ASCO 2025; Opdivo; relatlimab; clinical trial

ASCO 2025: Amgen’s Imdelltra Cuts Small Cell Lung Cancer Death Risk by 40% Versus Chemo

5 days ago talkbio0Tagged 2025, amgen, ASCO, death risk reduction, Imdelltra, Malignant neoplasm of lung, Overall Survival, Phase 3 trial, Small cell carcinoma of lung, tarlatamab-dlle

ASCO 2025; Amgen; Imdelltra; tarlatamab-dlle; lung cancer; small cell lung cancer; death risk reduction; overall survival; Phase 3 trial

J&J Presents First Survival Data for KLK2-Targeted Bispecific Pasritamig in Prostate Cancer at ASCO 2025

6 days ago talkbio0Tagged Antibodies, Bispecific, ASCO, Human Glandular Kallikrein 2, Immunotherapy, Johnson and Johnson, Malignant neoplasm of prostate, Metastatic castration-resistant prostate cancer, pasritamig, survival data

Johnson & Johnson; pasritamig; bispecific antibody; ASCO 2025; prostate cancer; KLK2; metastatic castration-resistant prostate cancer (mCRPC); survival data; immunotherapy

Bicara’s Ficerafusp Alfa Shows 46% 2-Year Survival Rate for Head and Neck Cancer Subset at ASCO 2025

6 days ago talkbio0Tagged 2025, Alfa, Antibody Therapy, ASCO, Bicara Therapeutics, Cancer of Neck, Head, Keytruda, Overall Survival, PD-L1, tumor shrinkage

ASCO 2025; Bicara Therapeutics; ficerafusp alfa; head and neck cancer; PD-L1; overall survival; antibody therapy; Keytruda; tumor shrinkage

Jazz Releases Full Survival Data for Zepzelca in Lung Cancer at ASCO 2025

2 weeks ago talkbio0Tagged ASCO, atezolizumab, IMforte trial, Jazz, lurbinectedin, Malignant neoplasm of lung, Overall Survival, Progression-Free Survival, Small cell carcinoma of lung, Tecentriq, Zepzelca

Jazz Pharmaceuticals; Zepzelca; lurbinectedin; lung cancer; small cell lung cancer; Tecentriq; atezolizumab; IMforte trial; overall survival; progression-free survival; ASCO 2025